Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
By taking certain antidepressant in early postoperative period，which is supposed to improve the psychological status of patients with osteoarthritis, explore the effect of certain antidepressant on the recovery of the early stage after the operation of knee joint replacement.
In this study, the investigators are going to investigate the efficacy of Duloxetine on pain, physical function, mental health and quality of life in patients underwent TKAs.
The control group is going to be given celecoxib 200mg/24h to 2 weeks after operation.On the basis of the above scheme, the treatment group is going to receiving duloxetine 60mg/24h to 8 weeks after operation.HAMD-17 scale, KSS scale, SF-36 scale and WOMAC scale will be used to evaluate the two groups before and after operation for 4 and 8 weeks.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| KSS scale | Active Comparator | Knee Society Score with Duloxetine Hydrochloride |
|
| HAMD-17 scale | Active Comparator | Hamilton Depression Score with Duloxetine Hydrochloride |
|
| SF-36 scale | Active Comparator | Medical Outcomes Study Short Form-36 score with Duloxetine Hydrochloride |
|
| WOMAC scale | Active Comparator | Western Ontario and McMaster Universities Index with Duloxetine Hydrochloride |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Duloxetine Hydrochloride | Drug | The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pain score of participants with Duloxetine as assessed by Western Ontario and McMaster Universities Index after 4 weeks of treatment. | A face-to-face questionnaire will be conducted by two trained interviewers | up to 6 months |
| Function score of participants with Duloxetine as assessed by Knee Society Score after 4 weeks of treatment. | A face-to-face questionnaire will be conducted by two trained interviewers | up to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Pain score of participants with Duloxetine as assessed by Western Ontario and McMaster Universities Index after 8 weeks of treatment. | A face-to-face questionnaire will be conducted by two trained interviewers | up to 6 months |
| Function score of participants with Duloxetine as assessed by Knee Society Score after 8 weeks of treatment. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| QI Zhiming, MD | Dalian Municipal Central Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dalian municipal central hospital | Dalian | Liaoning | 116000 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020370 | Osteoarthritis, Knee |
| D010003 | Osteoarthritis |
| D003863 | Depression |
| D010146 | Pain |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068736 | Duloxetine Hydrochloride |
| ID | Term |
|---|---|
| D013876 | Thiophenes |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D006573 | Heterocyclic Compounds, 1-Ring |
Not provided
Not provided
All patients will be randomly divided into two groups. The control group is going to be given celecoxib 200mg/24h to 2 weeks after operation. On the basis of the above scheme, the The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation.
Not provided
Not provided
Not provided
|
A face-to-face questionnaire will be conducted by two trained interviewers |
| up to 6 months |
| D001526 |
| Behavioral Symptoms |
| D001519 | Behavior |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D006571 |
| Heterocyclic Compounds |